Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

85P - Adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis

Date

03 Apr 2022

Session

Poster Display session

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

wang jie

Citation

Annals of Oncology (2022) 33 (suppl_2): S71-S78. 10.1016/annonc/annonc857

Authors

W. jie1, Y. Wu2, S. Lu3, Q. Wang4, S. Li5, W. Zhong6, Q. Wang7, W. Li8, B. Wang9, J. Chen10, Y. Cheng11, H. Duan12, G. Li13, L. Shan14, Y. Liu15, X. Huang16, A. Atasoy16, J. He17

Author affiliations

  • 1 Cancer Hospital, Chinese Academy of Medical Sciences, Beijing/CN
  • 2 Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
  • 3 Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN
  • 4 Zhongshan Hospital, Fudan University, Shanghai/CN
  • 5 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
  • 6 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou/CN
  • 7 Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou/CN
  • 8 The First Hospital of Jilin University, Changchun, Jilin/CN
  • 9 Yangzhou University, Yangzhou, Jiangsu/CN
  • 10 Tianjin Medical University General Hospital, Tianjin/CN
  • 11 Jilin Cancer Hospital, Changchun/CN
  • 12 Zhongshan Hospital, Xiamen University, Xiamen/CN
  • 13 GCP, Yunnan Cancer Hospital, Kunming/CN
  • 14 Xinjiang Medical University Affiliated Cancer Hospital, Urumqi/CN
  • 15 AstraZeneca, Shanghai/CN
  • 16 AstraZeneca, Cambridge/GB
  • 17 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 85P

Background

Osimertinib is a third-generation, EGFR-TKI with demonstrated efficacy in NSCLC, including CNS metastases. In Chinese pts with NSCLC, prevalence of EGFRm disease is high. In the global phase III ADAURA study (NCT02511106), adjuvant osimertinib demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) vs placebo (PBO) in pts with resectable stage II-IIIA (hazard ratio [HR] 0.17 [99.06% CI: 0.11, 0.26]; p<0.0001) and stage IB-IIIA (HR 0.20 [99.12% CI: 0.14, 0.30]; p<0.0001) EGFRm NSCLC. We present efficacy and safety data of a subgroup analysis of Chinese pts from ADAURA.

Methods

ADAURA enrolled adult pts with completely resected stage IB/II/IIIA NSCLC, EGFRm (Ex19del/L858R), and WHO PS 0–1. Adjuvant chemotherapy was allowed, per physician and pt choice before study entry. Pts were randomized 1:1 to osimertinib 80 mg once daily or PBO for up to 3 yrs (treatment completion) or until disease recurrence/discontinuation. Primary endpoint: investigator assessed DFS in pts with stage II–IIIA disease. Secondary endpoints included DFS in the overall population (stage IB–IIIA), overall survival and safety. Statistical analyses for this subgroup of Chinese pts were exploratory; p-values are nominal. Data cut-off (DCO): 17/01/20.

Results

Of 682 pts enrolled globally, 159 pts in mainland China were included in this subgroup analysis: osimertinib n=77, PBO n=82. Baseline characteristics were generally balanced across arms (osimertinib/PBO): median age 61/60 yrs, female 60/60%, stage IB 45/40%, stage II–IIIA 55/60%, Ex19del 47/38%, adjuvant chemotherapy 62/71%. At DCO, stage II–IIIA DFS HR was 0.16 (95% CI: 0.08, 0.31, p<0.0001; maturity 40%); stage IB–IIIA DFS HR was 0.18 (95% CI: 0.10, 0.33, p<0.0001; maturity 27%). A DFS benefit with osimertinib vs PBO was observed in all pre-specified subgroups of the China cohort with sufficient events for analysis. The safety profile of osimertinib was consistent with the global cohort and with the established safety of osimertinib.

Conclusions

Efficacy and safety data for Chinese pts in ADAURA were consistent with those reported for the global population.

Clinical trial identification

NCT02511106.

Editorial acknowledgement

Rachel Gater, PhD, of Ashfield MedComms, provided medical writing support that was funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

W. Jie: Financial Interests, Personal, Other, Honoraria: Beigene; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim; Financial Interests, Personal, Other, Honoraria: MSD. Y. Wu: Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria: Pfizer Inc.; Financial Interests, Personal, Other, Honoraria: Roche AG; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim; Financial Interests, Personal, Other, Honoraria: Eli Lilly & Co; Financial Interests, Personal, Other, Honoraria: MSD; Financial Interests, Personal, Other, Honoraria: Sanofi; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Pfizer Inc.; Financial Interests, Personal, Research Grant: Roche AG. S. Lu: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Hutchison MediPharma; Financial Interests, Personal, Advisory Board: Simcere; Financial Interests, Personal, Advisory Board: ZaiLab; Financial Interests, Personal, Advisory Board: GenomiCare; Financial Interests, Personal, Advisory Board: Yuhan Corporation; Financial Interests, Personal, Advisory Board: PrIME Oncology; Financial Interests, Personal, Advisory Board: Menarini; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Role, Consulting fees: AstraZeneca; Financial Interests, Personal, Advisory Role, Consulting fees: Roche; Financial Interests, Personal, Advisory Role, Consulting fees: Hansoh; Financial Interests, Personal, Advisory Role, Consulting fees: Hengrui Therapeutics; Financial Interests, Personal, Other, Corporate-sponsored research: AstraZeneca; Financial Interests, Personal, Other, Corporate-sponsored research: Hutchinson; Financial Interests, Personal, Other, Corporate-sponsored research: Bristol Myers Squibb; Financial Interests, Personal, Other, Corporate-sponsored research: Heng Rui; Financial Interests, Personal, Other, Corporate-sponsored research: Beigene; Financial Interests, Personal, Other, Corporate-sponsored research: Roche. Y. Liu: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. X. Huang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Atasoy: Financial Interests, Personal, Member of the Board of Directors: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.